276 related articles for article (PubMed ID: 23364466)
21. A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease.
Farrag MS; Kučerová J; Šlachtová L; Šeda O; Šperl J; Martásek P
Folia Biol (Praha); 2015; 61(6):227-32. PubMed ID: 26789144
[TBL] [Abstract][Full Text] [Related]
22. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation.
Gouya L; Puy H; Lamoril J; Da Silva V; Grandchamp B; Nordmann Y; Deybach JC
Blood; 1999 Mar; 93(6):2105-10. PubMed ID: 10068685
[TBL] [Abstract][Full Text] [Related]
23. X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria.
Brancaleoni V; Balwani M; Granata F; Graziadei G; Missineo P; Fiorentino V; Fustinoni S; Cappellini MD; Naik H; Desnick RJ; Di Pierro E
Clin Genet; 2016 Jan; 89(1):20-6. PubMed ID: 25615817
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietic Protoporphyria in a Japanese Population.
Mizawa M; Makino T; Nakano H; Sawamura D; Shimizu T
Acta Derm Venereol; 2019 Jun; 99(7):634-639. PubMed ID: 30938825
[TBL] [Abstract][Full Text] [Related]
25. Incomplete erythropoietic protoporphyria caused by a splice site modulator homozygous IVS3-48C polymorphism in the ferrochelatase gene.
Mizawa M; Makino T; Nakano H; Sawamura D; Shimizu T
Br J Dermatol; 2016 Jan; 174(1):172-5. PubMed ID: 26280465
[TBL] [Abstract][Full Text] [Related]
26. Clinical, biochemical, and genetic study of 11 patients with erythropoietic protoporphyria including one with homozygous disease.
Herrero C; To-Figueras J; Badenas C; Méndez M; Serrano P; Enríquez-Salamanca R; Lecha M
Arch Dermatol; 2007 Sep; 143(9):1125-9. PubMed ID: 17875872
[TBL] [Abstract][Full Text] [Related]
27. Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria.
Parera VE; Koole RH; Minderman G; Edixhoven A; Rossetti MV; Batlle A; de Rooij FW
Mol Med; 2009; 15(11-12):425-31. PubMed ID: 19693296
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of mutations in the ferrochelatase gene in Italian patients with erythropoietic protoporphyria.
Aurizi C; Schneider-Yin X; Sorge F; Macrì A; Minder EI; Biolcati G
Mol Genet Metab; 2007 Apr; 90(4):402-7. PubMed ID: 17196862
[TBL] [Abstract][Full Text] [Related]
29. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.
Wang Y; Langer NB; Shaw GC; Yang G; Li L; Kaplan J; Paw BH; Bloomer JR
Exp Hematol; 2011 Jul; 39(7):784-94. PubMed ID: 21627978
[TBL] [Abstract][Full Text] [Related]
30. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
[TBL] [Abstract][Full Text] [Related]
31. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
Leaf RK; Dickey AK
Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
[TBL] [Abstract][Full Text] [Related]
32. Novel mutations and phenotypic effect of the splice site modulator IVS3-48C in nine Swedish families with erythropoietic protoporphyria.
Wiman A; Floderus Y; Harper P
J Hum Genet; 2003; 48(2):70-6. PubMed ID: 12601550
[TBL] [Abstract][Full Text] [Related]
33. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria.
Rüfenacht UB; Gouya L; Schneider-Yin X; Puy H; Schäfer BW; Aquaron R; Nordmann Y; Minder EI; Deybach JC
Am J Hum Genet; 1998 Jun; 62(6):1341-52. PubMed ID: 9585598
[TBL] [Abstract][Full Text] [Related]
34. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.
Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI
Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505
[TBL] [Abstract][Full Text] [Related]
35. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.
Whatley SD; Ducamp S; Gouya L; Grandchamp B; Beaumont C; Badminton MN; Elder GH; Holme SA; Anstey AV; Parker M; Corrigall AV; Meissner PN; Hift RJ; Marsden JT; Ma Y; Mieli-Vergani G; Deybach JC; Puy H
Am J Hum Genet; 2008 Sep; 83(3):408-14. PubMed ID: 18760763
[TBL] [Abstract][Full Text] [Related]
36. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H
Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323
[TBL] [Abstract][Full Text] [Related]
37. Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria.
Whatley SD; Mason NG; Holme SA; Anstey AV; Elder GH; Badminton MN
J Invest Dermatol; 2007 Dec; 127(12):2790-4. PubMed ID: 17597821
[TBL] [Abstract][Full Text] [Related]
38. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP).
Ducamp S; Schneider-Yin X; de Rooij F; Clayton J; Fratz EJ; Rudd A; Ostapowicz G; Varigos G; Lefebvre T; Deybach JC; Gouya L; Wilson P; Ferreira GC; Minder EI; Puy H
Hum Mol Genet; 2013 Apr; 22(7):1280-8. PubMed ID: 23263862
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
